insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

What happened: insitro announced a worldwide exclusive research collaboration with AstraZeneca to discover novel targets and therapeutics in MASH and cardiomyopathies using insitro's Virtual Human causal AI discovery platform. Key numbers: $40 million upfront; up to approximately $1.46 billion in potential discovery, development, and commercial milestones; Why it matters: AstraZeneca will lead clinical development, regulatory work, and commercialization. insitro CEO Daphne Koller said the partnership pairs its biological precision with AstraZeneca's pharmaceutical expertise and scale. Market: +4.0% today ($162.06), -10.6% YTD, 1.3x vol — as of 22:46 UTC Coverage: 3 outlets in 24h

insitro announced a worldwide exclusive research collaboration with AstraZeneca to discover novel targets and therapeutics in MASH and cardiomyopathies using insitro's Virtual Human causal AI discovery platform.

AstraZeneca will lead clinical development, regulatory work, and commercialization. insitro CEO Daphne Koller said the partnership pairs its biological precision with AstraZeneca's pharmaceutical expertise and scale. Market: +4.0% today ($162.06), -10.6% YTD, 1.3x vol — as of 22:46 UTC